|
Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis Clinical research trials and Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis. Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis clinical trial. Subjects often receive the most expert healthcare possible for their Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "O" Clinical Trials Conditions > Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis  Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis
Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis
For Condition: Cardiovascular Diseases,Venous Thromboembolism,Venous Thrombosis
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To perform a randomized clinical trial comparing continuing one month of treatment with heparin in patients with deep venous thrombosis to standard care using heparin for five days and oral warfarin for three months.
Details: BACKGROUND: The study, a subproject within a SCOR in Thrombosis, should help to improve the long-term clinical outcome of patients with proximal deep-vein thrombosis (popliteal, femoral or iliac vein thrombosis) by improving their survival and reducing morbidity from recurrent thromboembolic events, and should help to determine if one or more specific biochemical measures, including antiphospholipid antibodies and activated factor VII, will define a subset of patients at increased risk of recurrent venous thromboembolism. The study is part of a SCOR in Hemostatic and Thrombotic Diseases, the RFA for which was released by the NHLBI in April 1994. DESIGN NARRATIVE: Warfarin Trial A multicenter, randomized clinical trial was conducted from March 1996 through January 2001 comparing warfarin therapy for three years to warfarin therapy for three months. The study was performed at thirteen participating hospitals in Oklahoma. The 600 hundred patients were recruited, randomized to either warfarin therapy for three years or warfarin therapy for three months and followed for at least three years. The primary outcome measure was total mortality. Secondary outcome measures included vascular death, objectively documented recurrent venous thromboembolism, and bleeding complications (major and minor). Additional specific aims included: determining the prevalence of antiphospholipid antibodies, antithrombomodulin antibodies, and activated protein C resistance in consecutive patients with proximal-vein thrombosis; determining if these measures, and/or the level of activated factor VII were associated with an increased risk of recurrent venous thromboembolic events, and if so, whether these events were reduced by continuing long term warfarin treatment. These latter specific aims were achieved by performing the laboratory parameters concurrently in patients entered into the clinical trial, and relating these measures to the clinical outcomes on long-term follow-up.
Eligibility:
Study Type: Observational, Retrospective Study
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: No eligibility criteria
Total Enrollment:
Location and Contact Information:
Overall Study Official:
GaryRaskob, , Oklahoma Medical Research Foundation
Additional Information:
Study ID Numbers: 4108;
Study Start Date: March 1996
Record last reviewed: October 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005684
Other Venous Thrombosis Studies:
1. Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED II)
2. Prevention of Recurrent Venous Thromboembolism (PREVENT)
3. Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis
4. Mutations, Hormone Therapy (HRT) and Venous Thromboembolism
5. Inflammation, Infection, and Future Cardiovascular Risk
Related Studies:
Other Venous Thrombosis Clinical Trials
Other Clinical Trials
Other Clinical Trials
Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis
|
|
|
|
|
|
|
|
